Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2138431 | Leukemia Research | 2009 | 4 Pages |
Abstract
Newly diagnosed children with ALL (n = 32) were treated on a protocol incorporating minimal residual disease (MRD)-based treatment decisions. MRD was monitored at 4 time points by semi-quantitative PCR detection of antigen receptor gene rearrangement, flow cytometry, quantitative RT-PCR detection of chimeric gene transcripts and overexpressed WT1 mRNA. Four patients positive for MRD at week 5 were treated with an intensified regimen. Median follow-up was 5.0 years (range 3.8–6.6 years) with a 4-year event-free survival rate of 93.8 ± 4.3%. This MRD-based treatment strategy seems to be highly successful and may improve the outcomes of children with ALL. A large study is warranted.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Akihisa Sawada, Naoki Sakata, Tomoko Kishimoto, Banryoku Higuchi, Maho Koyama, Osamu Kondo, Emiko Sato, Takayuki Okamura, Masahiro Yasui, Masami Inoue, Akira Yoshioka, Keisei Kawa,